Zenas BioPharma
Global biopharmaceutical company developing differentiated treatments for autoimmune diseases with significant unmet medical need, leveraging innovative approaches to modulate the immune system.
Notes
Zenas BioPharma is a global biopharmaceutical company focused on developing differentiated treatments for autoimmune diseases. The company is headquartered in Waltham, Massachusetts, with operations in multiple regions.
The company is developing a pipeline of novel therapeutics for autoimmune conditions, targeting diseases with significant unmet medical need. Zenas's approach focuses on innovative mechanisms to modulate the immune system and address the underlying causes of autoimmune pathology.
The company has attracted significant investment from leading healthcare investors including Novo Holdings.
Team
- John Tsai, M.D. - Chairman & Chief Executive Officer
- LinkedIn: linkedin.com/in/johntsai
- Former Chief Medical Officer at Novartis
- Neil Singla, M.D. - President
Additional Research Findings
- Investor: Novo Holdings
- Focus on autoimmune diseases
- Global operations (US and international)
- Experienced leadership from Big Pharma
- Waltham, Massachusetts headquarters
- Founded in 2021
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Novo Holdings | Hellerup, Denmark | biotech-focused | seedseries-a+3 | 13 |